Erratum

Diabetologia (1996) 39: 701–709

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients

S. Kumar¹, A. J. M. Boulton¹, H. Beck-Nielsen², F. Berthezene³, M. Muggeo⁴, B. Persson⁵, G. A. Spinas⁶, S. Donoghue⁷, S. Lettis⁷, P. Stewart-Long⁷, for the Troglitazone study group

¹ Department of Medicine, Manchester Royal Infirmary, Manchester, UK

² Medical Department, Odense University Hospital, Odense, Denmark

³ Department of Endocrinology, Hospital de L'Antiquaille, Lyon, France

⁴ Institute of Medical Pathology, University of Verona, Verona, Italy

⁵ Department of Medicine, Sahlgren Institute, Gothenburg, Sweden

⁶ Department of Endocrinology and Metabolism, University Hospital, Zurich, Switzerland

⁷ Medical Division, Glaxo Research and Development, Greenford, UK

Fig. 1. Effect of 12 weeks of treatment (geometric means) with troglitazone or placebo on fasting serum glucose. Troglitazone doses given once daily with breakfast

Fig. 2. Effect of 12 weeks of treatment (geometric means) with troglitazone or placebo on HbA_{1c}. Troglitazone doses given once daily with breakfast

Fig. 3. Effect of troglitazone on blood glucose and lipid parameters at week 12. Ratio of effect of each dose compared to placebo: adjusted geometric mean and 95 % confidence intervals (adjusted for baseline and any differences between countries)

The figure legends printed with Figs 1–3 in the above article were incorrect. The three figures are reprinted below together with the correct legend